Raymed Labs

Raymed_Labs06 May 2024

Pharmaceuticals

₹

0.00 (0.00%)

Lowest Today

Highest Today

Prev. Close

Today’s Open

52 Week High

52 Week Low

BUY

SELL

To Invest in Raymed Labs

Raymed Labs

Pharmaceuticals

Raymed_Labs06 May 2024

₹

0.00 (0.00%)

OverviewFundamentals

Corporate action

Peer comparison

Income Sheet

Balance sheet

Cash flow

Share holding

About Us

Corporate Action

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

All

Dividends

Bonus

Splits

Others

Ex-Date	Type	Description	Record Date
17-Apr-2024	BC	Outcome of Board Meeting pursuant to under Regulation 30 of SEBI (LODR) Regulations, 2015- change in Registered office of the Company within Local Limits	17-Apr-2024
25-Jan-2024	BC	RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve Unaudited Standalone Financial Results for the	06-Feb-2024
15-Dec-2023	BC	Intimation under Regulation 30(5) of SEBI LODR Regulations 2015-Authorisation & Contact details of Key Managerial Personnel of the Company	15-Dec-2023
27-Oct-2023	BC	RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve Unaudited Standalone Financial Results as per	04-Nov-2023
02-Aug-2023	BC	AGM 01/09/2023 Outcome of Board Meeting held on 02.08.2023 Book Closure dated from Saturday, 26th Day of August 2023 to Friday, the 1st day of September, 2023(both days inclusive) (As Per BS	01-Sep-2023

No Rights has been declared by Raymed_Labs

Book Closure

Record Date	Split Date	Purpose
17-Apr-2024	-	Outcome of Board Meeting pursuant to under Regulation 30 of SEBI (LODR) Regulations, 2015- change in Registered office of the Company within Local Limits
06-Feb-2024	-	RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/02/2024 inter alia to consider and approve Unaudited Standalone Financial Results for the
15-Dec-2023	-	Intimation under Regulation 30(5) of SEBI LODR Regulations 2015-Authorisation & Contact details of Key Managerial Personnel of the Company
04-Nov-2023	-	RAYMED LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2023 inter alia to consider and approve Unaudited Standalone Financial Results as per
01-Sep-2023	-	AGM 01/09/2023 Outcome of Board Meeting held on 02.08.2023 Book Closure dated from Saturday, 26th Day of August 2023 to Friday, the 1st day of September, 2023(both days inclusive) (As Per BS

Peer Comparison

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Scrip Name	Price	Daily Change	M.Cap (Cr)	1 Year Returns %	P/E (TTM)	PB Ratio
Raymed Labs Ltd ₹2.39(0.00/0.00%)	2.39	+0.00	1.02	11.68	0.00	-0.44
Astrazeneca Pharma India Ltd ₹5,409.40(-15.05/-0.28%)	5,409.40	-15.05	13,523.50	71.45	84.79	20.65
Bliss GVS Pharma Ltd ₹112.95(-6.15/-5.16%)	112.95	-6.15	1,182.48	56.07	15.60	1.20
Cipla Ltd ₹1,423.40(-1.35/-0.09%)	1,423.40	-1.35	114,924.60	54.70	34.95	4.44
Amrutanjan Health Care Ltd ₹753.45(-22.05/-2.84%)	753.45	-22.05	2,178.27	27.78	49.50	8.31
Abbott India Ltd ₹25,762.45(-382.00/-1.46%)	25,762.45	-382.00	54,745.21	15.92	47.79	17.61

Income Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Gross Sales	0.00	0.00	0.00	0.00	0.00	0.00
Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
Net Sales	0.00	0.00	0.00	0.00	0.00	0.00
Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
Other Income	0.00	0.00	0.00	0.02	0.00	0.00
Total Income	0.00	0.00	0.00	0.02	0.00	0.00
Total Expenditure	0.02	0.02	0.01	0.10	0.02	0.02
PBIDT	-0.02	-0.02	-0.01	-0.08	-0.02	-0.02
Interest	0.00	0.00	0.00	0.00	0.00	0.00
PBDT	-0.02	-0.02	-0.01	-0.08	-0.02	-0.02
Depreciation	0.00	0.00	0.00	0.00	0.00	0.00
Tax	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Reported Profit After Tax	-0.02	-0.02	-0.02	-0.08	-0.02	-0.02
Extra-ordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Profit After Extra-ordinary item	-0.02	-0.02	-0.02	-0.08	-0.02	-0.02

EPS (Unit Curr.)	-0.05	-0.04	-0.04	-0.18	-0.04	-0.06
EPS (Adj) (Unit Curr.)	-0.05	-0.04	-0.04	-0.18	-0.04	0.00
Calculated EPS (Unit Curr.)	-0.05	-0.04	-0.04	-0.18	-0.04	-0.06
Calculated EPS (Adj) (Unit Curr.)	-0.05	-0.04	-0.04	-0.18	-0.04	0.00
Calculated EPS (Ann.) (Unit Curr.)	-0.18	-0.16	-0.15	-0.74	-0.15	-0.23
Calculated EPS (Adj) (Ann.) (Unit Curr.)	-0.18	-0.16	-0.15	-0.74	-0.15	0.00
Book Value (Unit Curr.)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend (%)	0.00	0.00	0.00	0.00	0.00	0.00
Equity	4.27	4.27	4.27	4.27	4.27	4.27
Reserve & Surplus	0.00	0.00	0.00	0.00	0.00	0.00
Face Value	10.00	10.00	10.00	10.00	10.00	10.00

Public Shareholding (No. Of Shares)	0.00	0.00	0.00	0.00	0.00	0.00
Public Shareholding (% in Equity)	0.00	0.00	0.00	0.00	0.00	0.00

Pledged/Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Pledged/Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

Non Encumbered - No. of Shares	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Promoters Holding	0.00	0.00	0.00	0.00	0.00	0.00
Non Encumbered - % in Total Equity	0.00	0.00	0.00	0.00	0.00	0.00

PBIDTM(%)	0.00	0.00	0.00	0.00	0.00	0.00
PBDTM(%)	0.00	0.00	0.00	0.00	0.00	0.00
PATM(%)	0.00	0.00	0.00	0.00	0.00	0.00

Balance Sheet

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Standalone

Consolidated

Column	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19	Mar 18
SOURCES OF FUNDS :
Share Capital	4.27	4.27	4.27	4.27	4.27	4.27
Reserves Total	-6.58	-6.41	-6.33	-6.26	-6.20	-6.15
Equity Share Warrants	0.00	0.00	0.00	0.00	0.00	0.00
Equity Application Money	0.00	0.00	0.00	0.00	0.00	0.00
Total Shareholders Funds	-2.31	-2.14	-2.06	-1.99	-1.93	-1.88
Secured Loans	0.00	0.00	0.00	0.00	0.00	1.99
Unsecured Loans	0.05	0.05	2.21	2.07	2.05	0.05
Total Debt	0.05	0.05	2.21	2.07	2.05	2.04
Total Liabilities	-2.26	-2.09	0.15	0.08	0.12	0.16
APPLICATION OF FUNDS :
Gross Block	0.29	0.29	0.40	0.31	0.40	0.40
Less : Accumulated Depreciation	0.14	0.14	0.24	0.15	0.23	0.22
Less:Impairment of Assets	0.00	0.00	0.00	0.00	0.00	0.00
Net Block	0.15	0.15	0.16	0.16	0.17	0.18
Lease Adjustment	0.00	0.00	0.00	0.00	0.00	0.00
Capital Work in Progress	0.00	0.00	0.00	0.00	0.00	0.00
Producing Properties	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.00	0.00	0.00	0.00	0.00	0.00
Current Assets, Loans & Advances	0.00	0.00	0.00	0.00	0.00	0.00
Inventories	0.00	0.00	0.00	0.00	0.00	0.00
Sundry Debtors	0.00	0.02	0.02	0.02	0.02	0.02
Cash and Bank	0.00	0.00	0.00	0.00	0.00	0.00
Loans and Advances	0.00	0.06	0.06	0.06	0.07	0.07
Total Current Assets	0.01	0.09	0.09	0.09	0.09	0.09
Less : Current Liabilities and Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Current Liabilities	0.04	0.12	0.09	0.17	0.14	0.11
Provisions	0.00	0.00	0.00	0.00	0.00	0.00
Total Current Liabilities	0.04	0.12	0.09	0.17	0.14	0.11
Net Current Assets	-0.04	-0.03	0.00	-0.08	-0.05	-0.02
Miscellaneous Expenses not written off	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Assets	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax Liability	0.00	0.00	0.00	0.00	0.00	0.00
Net Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
Total Assets	0.11	0.13	0.16	0.09	0.12	0.16
Contingent Liabilities	0.00	0.00	0.00	0.00	0.00	0.00

Cash Flow

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

PARTICULARS	Mar 2023	Mar 2022
Cash and Cash Equivalents at Beginning of the year	0.00	0.00
Net Cash from Operating Activities	-0.16	-2.21
Net Cash Used In Investing Activities	0.16	2.21
Net Cash Used In Financing Activities	0.00	0.00
Net Inc./Dec In Cash And Cash Equivalents	0.00	0.00
Cash And Cash Equivalents At End Of The Year	0.00	0.00

Share Holding

These are actions taken by a company that impact the shareholders value directly. It is an event that brings material changes to a company and affects its stakeholders.

Promoter Shareholding

28.36%

FII Shareholding

0.00%

DII Shareholding

0.96%

Public Shareholding

70.68%

**Promoter pledged shareholding 28.36%

About Raymed Labs Ltd

Raymed Labs Ltd is in the Pharmaceuticals sector, having a market capitalization of Rs. 1.02 crores. It has reported a sales of Rs. 0 crores and a net profit of Rs. -0.02 crores for the quarter ended December 2018. The company management includes , Ajai Goyal,Nisha Goyal,Harsh Prabhakar,Poonam Sharma,Shreya Dave (Raymed Labs Ltd) among others.

Chairman

Registered office

103 Emperor 1 Sector 93A,Supertech Emerald Court,Noida,Uttar Pradesh,201304

FAX :

Background

Incorporation Year1992

Face Value₹10

Market Lot1

How to buy Raymed Labs shares on nse?

To buy Raymed Labs shares in Motilal Oswal, you just need to open a demat account and get your KYC documents verified

What is the Raymed Labs share price today?

The Raymed Labs shares price on nse is Rs.2.39 today.

What is the market cap of Raymed Labs shares on BSE ?

The company has a market capitalization of Rs.1.02Cr

What is the PE & PB ratio of Raymed Labs shares ?

PE is 0 and PB is -0.44

What is the 52 Week High and Low of Raymed Labs shares?

Raymed Labs stock price high: Rs.2.46 Raymed Labs stock price low: Rs.2.04